Literature DB >> 18667510

The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication.

Yasuo Ariumi1, Misao Kuroki, Hiromichi Dansako, Ken-Ichi Abe, Masanori Ikeda, Takaji Wakita, Nobuyuki Kato.   

Abstract

Cellular responses to DNA damage are crucial for maintaining genome integrity, virus infection, and preventing the development of cancer. Hepatitis C virus (HCV) infection and the expression of the HCV nonstructural protein NS3 and core protein have been proposed as factors involved in the induction of double-stranded DNA breaks and enhancement of the mutation frequency of cellular genes. Since DNA damage sensors, such as the ataxia-telangiectasia mutated kinase (ATM), ATM- and Rad3-related kinase (ATR), poly(ADP-ribose) polymerase 1 (PARP-1), and checkpoint kinase 2 (Chk2), play central roles in the response to genotoxic stress, we hypothesized that these sensors might affect HCV replication. To test this hypothesis, we examined the level of HCV RNA in HuH-7-derived cells stably expressing short hairpin RNA targeted to ATM, ATR, PARP-1, or Chk2. Consequently, we found that replication of both genome-length HCV RNA (HCV-O, genotype 1b) and the subgenomic replicon RNA were notably suppressed in ATM- or Chk2-knockdown cells. In addition, the RNA replication of HCV-JFH1 (genotype 2a) and the release of core protein into the culture supernatants were suppressed in these knockdown cells after inoculation of the cell culture-generated HCV. Consistent with these observations, ATM kinase inhibitor could suppress the HCV RNA replication. Furthermore, we observed that HCV NS3-NS4A interacted with ATM and that HCV NS5B interacted with both ATM and Chk2. Taken together, these results suggest that the ATM signaling pathway is critical for HCV RNA replication and may represent a novel target for the clinical treatment of patients with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667510      PMCID: PMC2546985          DOI: 10.1128/JVI.00351-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

Review 1.  Molecular virology of hepatitis C virus.

Authors:  N Kato
Journal:  Acta Med Okayama       Date:  2001-06       Impact factor: 0.892

Review 2.  Hepatitis C epidemiology.

Authors:  D L Thomas
Journal:  Curr Top Microbiol Immunol       Date:  2000       Impact factor: 4.291

3.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.

Authors:  Takaji Wakita; Thomas Pietschmann; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Zijiang Zhao; Krishna Murthy; Anja Habermann; Hans-Georg Kräusslich; Masashi Mizokami; Ralf Bartenschlager; T Jake Liang
Journal:  Nat Med       Date:  2005-06-12       Impact factor: 53.440

4.  Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system.

Authors:  Masanori Ikeda; Ken-Ichi Abe; Hiromichi Dansako; Takashi Nakamura; Kazuhito Naka; Nobuyuki Kato
Journal:  Biochem Biophys Res Commun       Date:  2005-04-22       Impact factor: 3.575

5.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.

Authors:  N Kato; M Hijikata; Y Ootsuyama; M Nakagawa; S Ohkoshi; T Sugimura; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

6.  DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication.

Authors:  Yasuo Ariumi; Misao Kuroki; Ken-ichi Abe; Hiromichi Dansako; Masanori Ikeda; Takaji Wakita; Nobuyuki Kato
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

7.  Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes.

Authors:  Keigo Machida; Kevin T-N Cheng; Vicky M-H Sung; Shigetaka Shimodaira; Karen L Lindsay; Alexandra M Levine; Ming-Yang Lai; Michael M C Lai
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-03       Impact factor: 11.205

8.  Limited suppression of the interferon-beta production by hepatitis C virus serine protease in cultured human hepatocytes.

Authors:  Hiromichi Dansako; Masanori Ikeda; Nobuyuki Kato
Journal:  FEBS J       Date:  2007-07-25       Impact factor: 5.542

9.  Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro.

Authors:  Nobuyuki Kato; Kazuo Sugiyama; Katsuyuki Namba; Hiromichi Dansako; Takashi Nakamura; Marika Takami; Kazuhito Naka; Akito Nozaki; Kunitada Shimotohno
Journal:  Biochem Biophys Res Commun       Date:  2003-07-04       Impact factor: 3.575

10.  Hepatitis C virus NS5B delays cell cycle progression by inducing interferon-beta via Toll-like receptor 3 signaling pathway without replicating viral genomes.

Authors:  Kazuhito Naka; Hiromichi Dansako; Naoya Kobayashi; Masanori Ikeda; Nobuyuki Kato
Journal:  Virology       Date:  2005-12-02       Impact factor: 3.616

View more
  34 in total

1.  Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest.

Authors:  Martin R Higgs; Hervé Lerat; Jean-Michel Pawlotsky
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  How do persistent infections with hepatitis C virus cause liver cancer?

Authors:  Jonathan K Mitchell; Stanley M Lemon; David R McGivern
Journal:  Curr Opin Virol       Date:  2015-09-29       Impact factor: 7.090

Review 3.  Viral manipulation of DNA repair and cell cycle checkpoints.

Authors:  Mira S Chaurushiya; Matthew D Weitzman
Journal:  DNA Repair (Amst)       Date:  2009-05-26

Review 4.  Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma.

Authors:  Amir Shlomai; Ype P de Jong; Charles M Rice
Journal:  Semin Cancer Biol       Date:  2014-01-20       Impact factor: 15.707

5.  Hepatitis C Virus Mediated Inhibition of miR-181c Activates ATM Signaling and Promotes Hepatocyte Growth.

Authors:  Tapas Patra; Keith Meyer; Ratna B Ray; Ranjit Ray
Journal:  Hepatology       Date:  2019-11-03       Impact factor: 17.425

6.  ATM supports gammaherpesvirus replication by attenuating type I interferon pathway.

Authors:  Eric J Darrah; Kyle P Stoltz; Mitchell Ledwith; Vera L Tarakanova
Journal:  Virology       Date:  2017-07-18       Impact factor: 3.616

Review 7.  Mechanisms of hepatocarcinogenesis in chronic hepatitis C.

Authors:  Jonathan K Mitchell; David R McGivern
Journal:  Hepat Oncol       Date:  2014-09-09

8.  ATM kinase is activated by sindbis viral vector infection.

Authors:  Christine Pampeno; Alicia Hurtado; Daniel Meruelo
Journal:  Virus Res       Date:  2012-03-29       Impact factor: 3.303

9.  Avian reovirus nonstructural protein p17-induced G(2)/M cell cycle arrest and host cellular protein translation shutoff involve activation of p53-dependent pathways.

Authors:  Julius L C Chulu; Wei R Huang; L Wang; Wen L Shih; Hung J Liu
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

10.  The Global Phosphorylation Landscape of SARS-CoV-2 Infection.

Authors:  Mehdi Bouhaddou; Danish Memon; Bjoern Meyer; Kris M White; Veronica V Rezelj; Miguel Correa Marrero; Benjamin J Polacco; James E Melnyk; Svenja Ulferts; Robyn M Kaake; Jyoti Batra; Alicia L Richards; Erica Stevenson; David E Gordon; Ajda Rojc; Kirsten Obernier; Jacqueline M Fabius; Margaret Soucheray; Lisa Miorin; Elena Moreno; Cassandra Koh; Quang Dinh Tran; Alexandra Hardy; Rémy Robinot; Thomas Vallet; Benjamin E Nilsson-Payant; Claudia Hernandez-Armenta; Alistair Dunham; Sebastian Weigang; Julian Knerr; Maya Modak; Diego Quintero; Yuan Zhou; Aurelien Dugourd; Alberto Valdeolivas; Trupti Patil; Qiongyu Li; Ruth Hüttenhain; Merve Cakir; Monita Muralidharan; Minkyu Kim; Gwendolyn Jang; Beril Tutuncuoglu; Joseph Hiatt; Jeffrey Z Guo; Jiewei Xu; Sophia Bouhaddou; Christopher J P Mathy; Anna Gaulton; Emma J Manners; Eloy Félix; Ying Shi; Marisa Goff; Jean K Lim; Timothy McBride; Michael C O'Neal; Yiming Cai; Jason C J Chang; David J Broadhurst; Saker Klippsten; Emmie De Wit; Andrew R Leach; Tanja Kortemme; Brian Shoichet; Melanie Ott; Julio Saez-Rodriguez; Benjamin R tenOever; R Dyche Mullins; Elizabeth R Fischer; Georg Kochs; Robert Grosse; Adolfo García-Sastre; Marco Vignuzzi; Jeffery R Johnson; Kevan M Shokat; Danielle L Swaney; Pedro Beltrao; Nevan J Krogan
Journal:  Cell       Date:  2020-06-28       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.